CVM Company Profile and Key Details

Q: Who are the executives of CVM?

Dr. Eyal Talor Ph.D.Chief Scientific OfficerMr. John CiprianoSenior Vice President of Regulatory AffairsMr. Geert R. Kersten Esq.Chief Executive & Financial Officer, Treasurer and DirectorDr. Daniel H. Zimmerman Ph.D.Senior Vice President of Research & Cellular ImmunologyMs. Patricia B. PrichepSenior Vice President of Operations & Corporation Sec.

AMEX : CVM

CEL-SCI

$4.90

-0.11-2.20%

At Close 4:00 PM

$5.20

+0.30+6.12%

After-Market 07:30 PM

66.25

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

CEL-SCI Corporation (CVM) stock declined over -2.20%, trading at $4.90 on AMEX, down from the previous close of $5.01. The stock opened at $5.00, fluctuating between $4.70 and $5.15 in the recent session.

Stock Snapshot

5.01

Prev. Close

33.67M

Market Cap

4.7

Day Low

-0.78

P/E Ratio

-6.27

EPS (TTM)

-0.48

Cash Flow per Share

Open

6.87M

Number of Shares

5.15

Day High

91.82%

Free Float in %

0.26

Book Value

82.37K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	5.00	5.15	4.70	4.90	74.33K
Feb 04, 2026	5.18	5.30	4.90	5.01	83.05K
Feb 03, 2026	5.44	5.44	5.00	5.24	54.02K
Feb 02, 2026	5.63	5.80	5.25	5.40	74.87K
Jan 30, 2026	5.94	6.01	5.43	5.80	82.73K
Jan 29, 2026	6.26	6.46	5.61	5.87	84.41K
Jan 28, 2026	6.61	6.68	6.09	6.30	87.1K
Jan 27, 2026	6.33	6.72	6.32	6.51	145.99K
Jan 26, 2026	6.70	6.75	5.99	6.18	211.49K
Jan 23, 2026	6.33	6.41	5.82	5.83	64.56K
Jan 22, 2026	5.32	6.56	5.32	6.41	127.32K
Jan 21, 2026	5.28	5.68	5.25	5.26	34.45K
Jan 20, 2026	5.16	5.88	5.02	5.25	95.17K
Jan 16, 2026	5.43	5.60	4.91	5.15	78.24K
Jan 15, 2026	5.23	5.59	4.90	4.99	72.79K
Jan 14, 2026	5.14	5.39	5.01	5.27	44.78K
Jan 13, 2026	5.12	5.30	4.91	5.08	63.65K
Jan 12, 2026	5.61	5.72	5.06	5.13	63.29K
Jan 09, 2026	5.90	5.95	5.44	5.48	58.4K
Jan 08, 2026	5.68	5.90	5.58	5.86	20.98K

Contact Details

Vienna, VA 22182

United States

https://cel-sci.com 703 506 9460

About Company

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

Stock Peers

TBXU

-0.2104-0.60%

Direxion Shares ETF Trust$35.11 PTN

0.13+0.82%

Palatin Technologies, Inc.$16.05 AGE

-1.5-11.90%

AgeX Therapeutics, Inc.$11.10 CYBN

0.1+1.22%

Cybin Inc.$8.28 ARMP

-0.02-0.25%

Armata Pharmaceuticals, Inc.$8.08 NSRX

-0.25-4.31%

Nasus Pharma Ltd.$5.55 PHGE

-0.73-13.80%

BiomX Inc.$4.56 CANF

0.21+5.20%

Can-Fite BioPharma Ltd.$4.25 PLX

0.01+0.34%

Protalix BioTherapeutics, Inc.$2.91 MAIA

-0.23-10.75%

MAIA Biotechnology, Inc.$1.91

Company Overview

CEL-SCI Corporation (AMEX:CVM) closed at $4.90 USD, losing -$0.11 (-2.20%) from the previous close of $5.01. The stock is currently mid-range between its 52-week high and low $1.98 and $20.40. With a market capitalization of about $33.67 million, CEL-SCI Corporation is classified as a micro-cap and shows market-like volatility (beta ~0.82). Key stats such as the average daily volume over the past year has been around 71.34 thousand shares, in line with its 52-week average. Headquartered in Vienna, VA, CEL-SCI Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Geert R. Kersten, the company employs approximately 43 people and listed since December 08, 1983. CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases.

Technical Performance

CVM has shown mixed momentum, gaining 2.34% over the past week and -40.68% over the past quarter, though year-to-date performance is down -0.19%. Short-term trend indicators are bullishly aligned (SMA20 -11.65%, SMA50 -15.32%, SMA200 -26.51%). The stock’s 14-day RSI is 40.42 (neutral), while the ATR of 0.59 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -75.99% below its high and over 147.47% above its low. Average 10-day trading volume of 99.78 thousand shares is slightly above the 3-month average of 70.03 thousand, indicating heightened recent market interest.

Valuation Metrics

CEL-SCI Corporation trades at a P/E ratio of -1.57, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.5 suggesting the stock is closer to book value. The P/FCF stands at -2.0, also above market averages.

Dividend & Fair Value

CEL-SCI Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.46. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

CEL-SCI Corporation generated EPS of -$7.71 over the past year. Five-year average earnings growth is 23.99%. The latest quarter delivered EPS of -$0.09. The next quarter is forecast at $nan. Next year's EPS is expected at -$40.85. CEL-SCI Corporation earnings surprise history is a consistent trend of beating forecasts. The quarter that ended January 13, 2025, missed forecasts by -10.0%. The prior quarter beat by 45.45%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in May 16, 2024.

Shareholding & Insider Activity

CEL-SCI Corporation has 6.88 million shares outstanding. The public float is 6.32 million shares, elevated short interest at 11.24% of float. This equals 766.46 thousand shares. The short ratio is 2.0 days. Institutional investors hold 6.73% of the float. Insiders own 8.18%. KINSOLVING C RICHARD holds 302.25 thousand shares, DE CLARA MAXIMILIAN has 251.23 thousand shares and PRICHEP PATRICIA B has 232.33 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, CEL-SCI has not generated any revenue. Returns are negative, with ROA at -0.09% and ROE at -159.25%.
On valuation metrics, CEL-SCI trades at a P/E of -1.57, P/S of 0.00 and P/B of 2.50. The current ratio is 2.26 and quick ratio is 2.26. Operationally, the company’s inventory turnover is 12.81 and cash conversion cycle is -71.22 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 588.07, supported by a cash flow-to-debt ratio of -0.00.

Quarterly Financial Highlights

For the quarter ended Sep 30, 2025, CEL-SCI posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $3.89M (margin 0.00%). Operating income was - $24.81M (margin 0.0%). Net income was- $25.41M (EPS - $6.27).
The company ended the quarter with $10.95B in cash and short-term investments, a total debt of $9.38B, and net debt of - $1.57B. Total assets were $28.16B, with equity of $15.96B. Financials further reflected weakness, with operating cash flow of - $17.12B, free cash flow of - $17.16B, and capital expenditures of - $38.11M.

Price Forecast & Outlook

Our AI price prediction model suggests that CEL-SCI Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.53%, with price expected at $5.22 by February 18, 2026, within a range of $4.56 to $5.87 3-Month Outlook: Projected rise of 5.51%, reaching $5.17 by May 05, 2026, with a range of $4.33 to $5.79. 1-Year Outlook: Projected gain of 5.51%, with price at $5.17 by February 04, 2027, within a range of $0.00 to $2.49.

Key Takeaways

CEL-SCI Corporation (AMEX:CVM) shares are flat -0.19% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows CEL-SCI Corporation trading at a premium to the broader market with a P/E of -1.57. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.17, suggesting 127.96% upside. Our AI forecast model points to short-term strength (6.53% over two weeks), a medium-term rise (5.51% over three months), and a longer-term gain (5.51% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current CEL-SCI Corporation (CVM) stock price?

CEL-SCI Corporation (AMEX: CVM) stock price is $4.90 in the last trading session. During the trading session, CVM stock reached the peak price of $5.15 while $4.70 was the lowest point it dropped to. The percentage change in CVM stock occurred in the recent session was -2.2% while the dollar amount for the price change in CVM stock was - $0.11.

CVM's industry and sector of operation?

The AMEX listed CVM is part of Biotechnology industry that operates in the broader Healthcare sector. CEL-SCI Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CVM?

Dr. Eyal Talor Ph.D.
Chief Scientific Officer
Mr. John Cipriano
Senior Vice President of Regulatory Affairs
Mr. Geert R. Kersten Esq.
Chief Executive & Financial Officer, Treasurer and Director
Dr. Daniel H. Zimmerman Ph.D.
Senior Vice President of Research & Cellular Immunology
Ms. Patricia B. Prichep
Senior Vice President of Operations & Corporation Sec.

How CVM did perform over past 52-week?

CVM's closing price is 147.47% higher than its 52-week low of $1.98 where as its distance from 52-week high of $20.40 is -75.98%.

How many employees does CVM have?

Number of CVM employees currently stands at 43.

Link for CVM official website?

Official Website of CVM is: https://cel-sci.com

How do I contact CVM?

CVM could be contacted at phone 703 506 9460 and can also be accessed through its website. CVM operates from 8229 Boone Boulevard, Vienna, VA 22182, United States.

How many shares of CVM are traded daily?

CVM stock volume for the day was 82.37K shares. The average number of CVM shares traded daily for last 3 months was 71.34K.

What is the market cap of CVM currently?

The market value of CVM currently stands at $33.67M with its latest stock price at $4.90 and 6.87M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	43
Beta	0.55
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	September
Sector	Healthcare
Industry	Biotechnology

CVM Company Profile and Key Details

CEL-SCI

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Earnings & Analyst Outlook

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways